About the Authors
- Sharad P. Adekar
-
Affiliations Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, United States of America, Immunome, Inc., Wynnewood, Pennsylvania, United States of America, Augmenta Biologicals, LLC, Wynnewood, Pennsylvania, United States of America
- Andrew T. Segan
-
Affiliation Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, United States of America
- Cindy Chen
-
Affiliation Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, United States of America
- Rodney Bermudez
-
Affiliation Immunome, Inc., Wynnewood, Pennsylvania, United States of America
- M. D. Elias
-
Affiliation Division of Infectious Diseases and Environmental Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America
- Bernard H. Selling
-
Affiliation Impact Biologicals, Inc. Wallingford, Pennsylvania, United States of America
- B. P. Kapadnis
-
Affiliation Department of Microbiology, University of Pune, Pune, India
- Lance L. Simpson
-
Affiliation Division of Infectious Diseases and Environmental Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America
- Paul M. Simon
-
* E-mail: scott.dessain@gmail.com (SKD); simonpm@augmentabio.com (PMS)
Affiliation Augmenta Biologicals, LLC, Wynnewood, Pennsylvania, United States of America
- Scott K. Dessain
-
* E-mail: scott.dessain@gmail.com (SKD); simonpm@augmentabio.com (PMS)
Affiliation Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, United States of America
Competing Interests
The authors have read the journal's policy and have the following conflicts: SPA and RB are part-time employees of Immunome, Inc., a company that has optioned rights to the antibodies described in this report. BHS is the president of Impact Biologicals, Inc. PMS is the inventor of the FP and the President of Augmenta, LLC. SKD is a founder and Chief Scientific Officer of Immunome, Inc. and has an equity interest in the company. SKD does not receive research support or consulting fees from Immunome, Inc., Augmenta Biologicals, LLC, or Impact Biologicals, Inc. A provisional US Patent application has been filed on the experiments described, "Toxin Clearance", Inventors SPA, SKD, PMS, and has been assigned to LIMR and Augmenta, LLC. These relationships do not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: SPA ATS MDE BHS LLS PMS SKD. Performed the experiments: SPA ATS CC RB MDE BHS PMS. Analyzed the data: SPA ATS MDE BPK LLS PMS SKD. Contributed reagents/materials/analysis tools: SPA MDE BHS LLS PMS. Wrote the paper: SPA ATS MDE PMS SKD. Edited the manuscript: BHS BPK LLS.